menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    FDA blasts Bristol Myers over misleading Krazati efficacy claims

    FIERCE PHARMA

    BMS cuts hundreds of Mirati staffers shortly after buyout

    FIERCE PHARMA

    Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics

    BUSINESSWIRE

    Bristol Myers gets regulatory clearance to close Mirati deal

    ENDPTS

    EU body endorses Mirati`s KRAS drug for lung cancer after second look

    PR NEWSWIRE

    Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration

    GLOBENEWSWIRE

    Securities filing details BMS` years-long courtship of Mirati

    FIERCE PHARMA

    Mirati Presents Results Evaluating the Combination of Adagrasib in NSCLC

    PRESS RELEASE

    Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal

    REUTERS

    Sanofi weighs acquisition of Mirati: Bloomberg

    FIERCE PHARMA

    Mirati To Present Updated Clinical Data at ESMO Congress 2023

    PRESS RELEASE

    Mirati Presents Data from KRYSTAL-1 Study Demonstrating Durable Response

    PR NEWSWIRE

    Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    PRESS RELEASE

    Bazhenova Details Potential Pathways Forward for Targeting KRAS in NSCLC

    ONCLIVE

    Bayer enlists Jürgen Eckhardt to leap into an additional role; Mirati tops list of multiple CFO exits

    ENDPTS

    Mirati Announces Departure of Chief Financial Officer Laurie Stelzer

    PR NEWSWIRE

    Mirati Announces Closing of Upsized Public Offering

    PRESS RELEASE

    Mirati Therapeutics Announces Pricing of Upsized Public Offering

    PRESS RELEASE

    Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719

    PR NEWSWIRE

    Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek

    PRESS RELEASE

    Mirati Therapeutics Announces Proposed Public Offering

    PRESS RELEASE

    Mirati Therapeutics Reports Second Quarter 2023 Financial Results

    PR NEWSWIRE

    Mirati parts ways with CEO, unveils new KRAS-Keytruda trial plan

    FIERCE PHARMA

    Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    PRESS RELEASE

    DOJ accuses billionaire of insider trading in Solid Bio, Mirati

    FIERCE BIOTECH

    Mirati Therapeutics® to Report Second Quarter 2023 Financial Results

    PRESS RELEASE

    Mirati`s lung cancer drug fails to win EU regulator`s backing

    PRESS RELEASE

    Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D as New Independent Director

    PR NEWSWIRE

    Journal of Clinical Oncology Publishes Clinical Results of Adagrasib

    PRESS RELEASE

    Mirati to Participate at the Goldman Sachs 44th Annual Global Conference 2023

    FINANCE YAHOO

    Mirati`s wait for next lung cancer med ends in phase 3 failure

    FIERCE BIOTECH

    Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study

    PRESS RELEASE

    Mirati`s KRAS drug Krazati beat estimates in first full quarter

    FIERCE PHARMA

    Mirati Therapeutics Reports First Quarter 2023 Financial Results

    PRESS RELEASE

    Mirati Therapeutics & Sarah Cannon Research Institute Announce Strategi

    BIOSPACE

    Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    PRESS RELEASE

    Next round of KRAS drugs follow footsteps of Amgen and Mirati

    FIERCE BIOTECH

    Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference

    PR NEWSWIRE

    Mirati to Participate at the 43rd Annual Cowen Health Care Conference

    PRESS RELEASE

    Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results

    PRESS RELEASE

    Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    PRESS RELEASE

    Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences

    PR NEWSWIRE

    Mirati Announces IND Clearance by FDA Enabling Phase 1 Initiation for MRTX1133

    PR NEWSWIRE

    Mirati eyes `highest opportunity for capital` in pipeline build

    FIERCEBIOTECH

    Apple Tree biotech emerges with antibodies that might pair with KRAS drugs

    ENDPTS

    JPM23, Day 1: Lilly`s busy schedule, Mirati`s new pipeline

    FIERCE BIOTECH

    Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    PRESS RELEASE

    Don`t Ignore The Insider Selling In Mirati Therapeutics

    SIMPLYWALL

    Mirati to Present at the 41st Annual J.P. Morgan Healthcare Conference

    PRESS RELEASE

    Mirati announces AdagrasibReceives Breakthrough Therapy Designation from FDA

    PRESS RELEASE

    Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    PRESS RELEASE

    QIAGEN receives FDA approval for companion diagnostic to Mirati’s KRAZATI

    BUSINESSWIRE

    U.S. FDA approves Mirati`s lung cancer drug Adagrasib

    PRNEWSWIRE

    Mirati to focus KRAS inhibitor, Keytruda combo on low PD-L1 lung cancer

    FIERCEBIOTECH

    Mirati Therapeutics Presents Results Evaluating Adagrasib and Pembrolizumab

    PRESS RELEASE

    Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

    PRESS RELEASE

    Mirati`s sitravatinib yet to improve survival at interim review

    FIERCEBIOTECH

    Mirati Therapeutics to Present Late-Breaking Combination Results at ESMO IO

    PRESS RELEASE

    Mirati gauging sale interest of Big Pharmas — report

    ENDPTS

    Mirati is once again the subject of takeover talks: report

    FIERCEBIOTECH

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.